Cadefrecitinib

Small molecule

Also known as GLPG3667

DiscontinuedTYK2
Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2026-11-11), as a strategic decision by the sponsor

Lakefront Biotherapeutics discontinued the GLPG3667 (cadefrecitinib) programme after discussions with potential partners. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Featured evidence outside this drug's tracked markets:NCT04097938 · Healthy · Phase 1 · completed · ungraded

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Other / comorbidity
Phase 1 (6)
Other / comorbidity
NCT05335447 · Lakefront Biotherapeutics NV
2022-04-19 – 2022-06-03 · Healthy
What this study did
NCT05272683 · Lakefront Biotherapeutics NV
2022-02-28 – 2022-04-22 · Healthy
What this study did
NCT04976270 · Lakefront Biotherapeutics NV
2021-07-20 – 2022-01-14 · Healthy
What this study did
NCT04594928 · Lakefront Biotherapeutics NV
2020-10-19 – 2021-05-04 · Plaque Psoriasis
What this study did
NCT04736927 · Lakefront Biotherapeutics NV
2021-01-15 – 2021-02-25 · Healthy
What this study did
NCT04097938 · Lakefront Biotherapeutics NV
2019-09-18 – 2020-07-06 · Healthy
What this study did

Competitive landscape

This mechanism is crowded: 13 other tracked programmes target it, 13 of them ahead of this one.

This drug's own stage for Dermatomyositis: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cadefrecitinib: this drugDiscontinuedSmall moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
Brepocitinib (Lisraya)ApprovedSmall moleculeTYK2/JAK1not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
PF-06823859Phase 3Monoclonal antibodyInterferon beta (IFN-beta)not yet gradedNo reviewed efficacy summary in this indication
Descartes-08Phase 1/2Cell therapyBCMA (B-cell maturation antigen)not yet gradedNo reviewed efficacy summary in this indication
A-005
Phase 1(overall)
Small moleculeTYK2
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

18 December 2025Topline resultGALACELA (NCT05856448) in SLE did not meet its primary endpoint (SRI-4 at week 32)